| News

BaseLaunch startup Polyneuron raises new financing

14.05.2018

Polyneuron Pharmaceuticals has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active substance for the treatment of the autoimmune disease anti-MAG neuropathy, among others.

Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals

Polyneuron Pharmaceuticals has announced the closing of a 3.1 million Swiss franc financing round. The financing was led by EVA Basel, which specializes in supporting startups, and included the Zürcher Kantonalbank and private investors.

The Basel-based pharmaceutical company will use the proceeds to advance its lead candidate, PN-1007, to clinical development for the treatment of the autoimmune disease anti-MAG neuropathy. It will also advance its Antibody-Catch technology platform, which enables the development of drugs that eliminate autoimmune-disease causing autoantibodies, while leaving the immune system intact.

Since the initial seed financing tranche, the company has met several key milestones, said CEO Ruben Herrendorff. For instance, it delivered a preclinical proof of principle with PN-1007, concluded a key licensing agreement with the University of Basel, and expanded its team – including the appointments of Gerhard Müller as Chairman and Michael Wacker as Chief Business Officer. Wacker is the co-founder, Chief Scientific Officer and member of the board of directors of the Schlieren-based company GlycoVaxyn, which was acquired by the UK’s GlaxoSmithKline in 2015.

Polyneuron Pharmaceuticals was founded in 2014 as a spin-off of the University of Basel and is headquartered in the startup centre Basel Inkubator.

Polyneuron Pharmaceuticals is part of the startups that were selected for Phase II of the BaseLaunch accelerator program.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
For Swiss startups, China might be closer than it seems
Basel Area Business & Innovation, Invest

For Swiss startups, China might be closer than it seems

China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
RocketVax secures partners for coronavirus vaccine in Basel
Basel Area Business & Innovation, Innovation

RocketVax secures partners for coronavirus vaccine in Basel

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...

Read More
Bright Peak secures investment of 107 million dollars
Basel Area Business & Innovation, Innovation, Invest

Bright Peak secures investment of 107 million dollars

Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm...

Read More
LCB lands major contract
Basel Area Business & Innovation, Innovation, Invest

LCB lands major contract

LCB Sàrl is active in the areas of Human Machine Interface as well as software and electronics development. The company...

Read More
1 2 3 28

Do you have a question? We'd like to hear from you.